Last A$0.04 AUD
Change Today -0.001 / -2.38%
Volume 2.7M
PRR On Other Exchanges
As of 1:35 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

prima biomed ltd (PRR) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/12/13 - A$0.11
52 Week Low
10/14/13 - A$0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PRIMA BIOMED LTD (PRR)

Related News

No related news articles were found.

prima biomed ltd (PRR) Related Businessweek News

No Related Businessweek News Found

prima biomed ltd (PRR) Details

Prima BioMed Ltd., a biotechnology company, researches, develops, and commercializes licensed medical biotechnology products in Australia. Its lead product includes CVac, a cancer vaccine for patients in remission, which has completed two human clinical trials. The company is also developing oral vaccine against human papilloma virus, a virus associated with development of cervical cancer. Prima BioMed Ltd. is based in Sydney, Australia.

30 Employees
Last Reported Date: 08/30/13

prima biomed ltd (PRR) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: A$213.9K
Chief Technical Officer
Total Annual Compensation: A$290.2K
General Counsel and Company Secretary
Total Annual Compensation: A$104.3K
Total Annual Compensation: A$312.3K
Compensation as of Fiscal Year 2013.

prima biomed ltd (PRR) Key Developments

Prima Biomed Ltd. Announces Executive Changes

The Board of Prima Biomed Ltd. announced that Marc Voigt has been appointed as Chief Executive Officer of Prima. Mr. Voigt, Prima's Chief Business Officer and Chief Financial Officer as well as General Manager of the company's European Operations, replaces US based Matthew Lehman who will step down from the Board but remain as an adviser to the company to facilitate an orderly transition. Following his appointment as CEO, Marc Voigt will join the Prima Board as an Executive Director. Marc has more than 16 years of experience in the financial and biotech industry, having joined the Prima team in 2011 as the General Manager, European Operations based in Berlin, Germany.

Prima BioMed Ltd Announces CVac Demonstration of Positive Trend in Overall Survival in Second Remission Ovarian Cancer

Prima BioMed Ltd. announced that CVac has demonstrated a positive trend in overall survival (OS) over standard of care in second remission ovarian cancer patients in the CAN-003 protocol. In second remission patients (n=20) from CAN-003, median OS for control group patients was 26.25 months while a median for CVac patients was not yet reached after 30 months (hazard ratio=0.17; p=0.07). Medians for the control group and CVac treated patients have not yet been reached for first remission patients. CAN-003 is a 63-patient phase 2 study evaluating the effects of CVac, as compared to an observational standard of care arm (OSC), in epithelial ovarian cancer patients in complete remission after first or second line treatment. In accordance with the protocol design, the first seven patients on the trial were all assigned to receive CVac in order to test the comparability of product manufacturing in a new facility. The subsequent 56 patients were randomized 1:1 to either the CVac group or observational standard of care (OSC) and included in the intent-to-treat analysis. 36 patients were in first remission (19 patients were assigned to CVac and 17 to OSC) and 20 patients were in second remission (10 patients were each assigned to CVac or OSC). Final PFS data was analysed after thorough quality control reviews of investigator-evaluated progression and appropriate censoring of data from patients who had not progressed during the study. The primary objectives of the trial are to determine the safety of CVac administration and to determine CVac's effect on progression-free survival. Secondary objectives of the trial are to determine CVac's effect of overall survival and to evaluate host immunologic responses to CVac.

Prima BioMed Ltd announces CVac(TM) Granted Fast Track Designation by Fda

Prima BioMed Ltd. announced that the United States Food and Drug Administration ("FDA") granted Fast Track Designation to the CVac clinical development program at Prima. This program is intended to improve overall survival in patients with relapsed platinum-sensitive epithelial ovarian cancer who enter a second complete remission. Prima will work closely with the FDA in accelerating its development program for CVac to potentially bring this treatment option to patients in the U.S.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRR:AU A$0.04 AUD -0.001

PRR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRR.
View Industry Companies

Industry Analysis


Industry Average

Valuation PRR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.6x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRIMA BIOMED LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at